Persistent Depressive Disorder

Cross-source consensus on Persistent Depressive Disorder from 1 sources and 5 claims.

1 sources · 5 claims

Risks & contraindications

Comparisons

Evidence quality

Other

Highlighted claims

Persistent depressive disorder affects about 20% to 30% of people with depression and has an estimated lifetime prevalence of 3% to 6%. — Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled changePDD trial
Persistent depressive disorder is associated with psychosocial impairment, comorbidities, suicidality, and treatment resistance. — Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled changePDD trial
There is a lack of evidence-based inpatient treatments for people with persistent depressive disorder. — Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled changePDD trial
The trial requires participants to have DSM-5 persistent depressive disorder, depression severity of at least 20 on HDRS-24, and treatment resistance. — Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled changePDD trial
Inpatients with persistent depressive disorder have lower response rates and higher relapse risk than inpatients with non-chronic depression. — Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled changePDD trial